Clinical trials: Epithelial Neoplasms, Malignant
Non Small Cell Lung Cancer (NSCLC)
Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Combining nimotuzumab to gefitinib may not only potentiate cellular cytotoxicity, but may also assist in overcoming inherent or acquired resistance to gefitinib alone.
- Trial name
- DATE (NCT01498562)
- Testing
- Gefitinib and Nimotuzumab, Gefitinib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Nasopharyngeal Carcinoma
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication…
- Trial name
- NCT06239727
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2)
- Where
- 26 sites in China
- Volunteers
- 593 people
- Sponsor
- Sun Yat-sen University
Renal Cancer
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.
- Trial name
- NCT00293527
- Testing
- Interferon Alpha-2b
- Sponsor
- Ohio State University Comprehensive Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
The study consists of a retrospective observational, multicenter study in which the fundamental exposure factor being investigated is a drug (rucaparib).
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04539327
- Testing
- Rucaparib
- Where
- 23 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Lung Cancer, Medication Adherence
Implementation Strategies for Monitoring Adherence in Real Time
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies.
- Conditions
- Lung Cancer, Medication Adherence, Symptoms and Signs
- Trial name
- iSMART (NCT04347161)
- Testing
- Conversational Agent/Chatbot, Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic/Advanced Renal Cell Carcinoma
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center Principal assumption : the proportion of patients presenting…
- Trial name
- RENACALL (NCT02187042)
- Testing
- Best supportive care, call center
- Where
- 13 sites in France
- Volunteers
- 70 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer, NSCLC
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
This phase 2 study is designed to evaluate the safety and activity of TH-4000 a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced NSCLC.
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
- Trial name
- TH-4000 (NCT02454842)
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 12 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Rain Oncology Inc
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003670
- Testing
- arzoxifene hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00569673
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Where
- 37 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gynecologic Oncology Group
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
This phase II trial studies how well platinum-based chemotherapy works when given together with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04262869
- Testing
- Carboplatin, Durvalumab, Paclitaxel
- Sponsor
- Emory University
Melanoma (Skin), Skin Cancer
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma.
- Conditions
- Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
- Trial name
- NCT03543969
- Testing
- Encorafenib, Binimetinib, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cerebral Astrocytoma, High Grade
Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma
The objectives of the trial are: To determine the localisation within the primary tumor of the therapy resistant cells, before and during radiotherapy to determine a possible accurate boost volume.
- Trial name
- NCT00643591
- Testing
- imaging (dynamic PET-CT scan)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Maastricht Radiation Oncology
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade…
- Conditions
- Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
- Trial name
- NCT03608618
- Testing
- MCY-M11, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- MaxCyte, Inc.
Adult Glioblastoma
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling.
- Trial name
- TGEN (NCT02060890)
- Testing
- specialized tumor board recommendation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Solid Tumor, Metastatic Solid Tumor
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
- Conditions
- Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT05678010
- Testing
- AZD1390, Stereotactic Body Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Renal Cell, Kidney Disease
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
- Conditions
- Carcinoma, Renal Cell, Kidney Disease, Kidney Cancer
- Trial name
- NCT00854620
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Brain Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas.
- Trial name
- NCT00002620
- Testing
- carmustine, chemotherapy, mitolactol
- Where
- 14 sites in Austria, Belgium and 6 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroendocrine Tumor, Carcinoid Tumor
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00942682
- Testing
- Sorafenib, RAD001
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Carcinoma
L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .
- Trial name
- CARPAN (NCT01330823)
- Testing
- L-Carnitine
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- University Medicine Greifswald
Sarcoma, Neuroblastoma
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Background: Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT01130623
- Testing
- Pazopanib (GW786034)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.